119-41-5

Usage

Uses

Used in Pharmaceutical Industry:
Eloxate is used as an antibiotic for the treatment of various bacterial infections, including urinary tract infections, respiratory tract infections, and skin infections. Its application is based on its mechanism of action, which involves the inhibition of essential enzymes required for bacterial DNA replication and repair, thereby controlling the spread and severity of infections.
Used in Clinical Settings:
In clinical practice, Eloxate is utilized as a therapeutic agent to combat bacterial infections, particularly those that are resistant to other commonly used antibiotics. Its use is carefully managed to avoid potential drug interactions and allergic reactions, ensuring patient safety and optimal treatment outcomes.

InChI:InChI=1/C19H16O5/c1-2-22-19(21)12-23-14-8-9-15-16(20)11-17(24-18(15)10-14)13-6-4-3-5-7-13/h3-11H,2,12H2,1H3

Upstream product

• 6665-86-7 7-hydroxyflavone 
• 105-36-2 ethyl bromoacetate 
• 97980-65-9 2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)acetic acid 
• 105-39-5 chloroacetic acid ethyl ester 
• 40433-33-8 (4-acetyl-3-hydroxyphenoxy)acetic acid ethyl ester 
• 98-88-4 benzoyl chloride 
• 7436-90-0 2,2-dibromostyrene 
• 96089-43-9 2-hydroxy-4-<(carboxymethyl)oxy>benzaldehyde ethyl ester 
• 5465-06-5 <4-(benzoyloxy)-2-hydroxybenzoyl>benzoylmethane 
• 38256-07-4 1-(2',4'-dihydroxyphenyl)-3-phenyl-propane-1,3-dione 
• 102019-14-7 (4-acetyl-3-benzoyloxy-phenoxy)-acetic acid ethyl ester 
• 2430-55-9 7-ethoxy-carbonylmethoxyflavanone 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 21591-05-9 [3-hydroxy-4-(3-oxo-3-phenyl-propionyl)-phenoxy]-acetic acid ethyl ester 

Downstream Products

• 97980-65-9 2-((4-oxo-2-phenyl-4H-chromen-7-yl)oxy)acetic acid 
• 301206-12-2 N-(6-amino-3-methyl-2,4-dioxo-1-phenyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-(4-oxo-2-phenyl-4H-chromen-7-yloxy)-acetamide 

Relevant academic research and scientific papers

Synthesis and anti-inflammatory in vitro, in silico, and in vivo studies of flavone analogues

Chrysin and 7-hydroxy flavone were prepared by Baker-Venkatraman rearrangement followed by esterification at 7th position and replacement of ester with acetamide linking to different heterocyclic moieties synthesized 13a-g and 14a-g series of flavones analogues. These were screened against COX-2 and COX-1 enzymes for inhibition by in vitro assay and COX-2 for in silico docking studies. The compound 14a was found to be most active with IC50 of 3.11 μM concentration, with highest binding energy of -12.4 kcal/mole and 77.2 and 80.5 % inhibition at 3 and 5 h post-carrageenan induced in paw oedema.

Rh-Catalyzed aldehydic C-H alkynylation and annulation

Novel Rh-catalyzed aldehydic C-H bond alkynylation and annulation for the in situ synthesis of chromones and aurones are described. It involves the sequential aldehyde C-H bond alkynylation of salicylaldehyde with in situ generated 1-bromoalkyne from 1,1-

Synthesis and biological evaluation of Complex I inhibitor R419 and its derivatives as anticancer agents in HepG2 cells

In this study, Complex I inhibitor R419 was firstly revealed to have significant anticancer activity against HepG2 cells (IC50 = 5.2 ± 0.9 μM). Based on this finding, a series of R419 derivatives were synthesized and biologically evaluated. As results, 9 derivatives were found to have obvious anticancer activity. Among them, H20 exhibited the most potent activity (IC50 = 2.8 ± 0.4 μM). Mechanism study revealed that H20 caused severe depletion of cellular ATP, dose-dependently activated AMPK, decreased Bcl-2/Bax ratio and induced necrotic cell death. Most importantly, H20 displayed definite inhibitory activity against Complex I.

COMPOUNDS FOR IMMUNOPOTENTIATION

Methods of stimulating an immune response and treating patients responsive thereto with 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, nucleoside analogs, and other small molecules are disclosed.

Synthesis and biological evaluation of CX-659S and its related compounds for their inhibitory effects on the delayed-type hypersensitivity reaction

In order to find novel nonsteroidal compounds possessing an inhibitory activity against delayed-type hypersensitivity (DTH) reactions, we conducted random screening using a picryl chloride (PC)-induced contact hypersensitivity reaction (CHR) in mice, and found compound 1 as a lead compound. Then we synthesized and evaluated an extensive series of 5-carboxamidouracil derivatives focused on both the uracil and the antioxidative moieties. Among them, we found that the hindered phenol moiety was necessary to exhibit the activities; especially, compounds 28a-28c having the partial structure of vitamin E were found to exert potent activities against the DTH reaction by both oral and topical administration. And compound 28c showed antioxidative activity against lipid peroxidation with an IC50 of 5.9μM. Compound 28c (CX-659S) was chosen as a candidate drug for the treatment of cutaneous disorders such as atopic dermatitis and allergic contact dermatitis. Copyright (C) 2000 Elsevier Science Ltd.

Synthesis of carboxylated flavonoids as new leads for LTD4 antagonists

A series of 3'- and 5'-carboxylated chalcones, 6- or 8-carboxylated flavones and 6-carboxylated flavanones, -flavanols and -flavans were prepared. The compounds were tested for their inhibitory activities against leukotriene D4 (LTD4) induced contraction of guinea-pig ileum. A new and convenient synthetic route to 3-acetyl-2-hydroxybenzoic acid (Id), a key intermediate for the synthesis of 3'-carboxy-2'-hydroxychalcones and 8-carboxylated flavones, was developed. The activities of the tested compounds ranged from 0 to 63% inhibition at 10-5 M drug concentration against a single challenge of 10-8 M LTD4. Several compounds were tested in a radioligand binding assay against [3H]LTD4 on guinea-pig lung membrane. The quinoline-containing chalcone 12 and flavone 17 were found to exhibit significant but weak affinities for LTD4 receptors with pK(D)-values of 4.95 and 4.83, respectively and are interesting lead structures for the development of rigid LTD4 antagonists. In contrast, the rest of the compounds tested in the binding assay did not show significant displacement of the radioligand, implying that for these compounds the functional activity is probably not caused by competitive antagonism at the LTD4 receptor. The exact mechanism of the relaxant activity remains unclear.